Pharma BD Deal Intelligence
Nearly 20 years and roughly $454M later, GSK's dAb platform bet has produced no approved drug — the flagship Domantis-derived TNFR1 program was discontinued after immunogenicity failures, and GSK even lost core dAb patent protection to rival Ablynx.
Full analysis, sources & comparables →GSK announced acquisition of Domantis for £230M cash; Domantis to integrate into GSK's Biopharmaceuticals Centre of Excellence for Drug Discovery in Cambridge,…
Science|Business flagged the high price for an exclusively preclinical portfolio: '£230M for a preclinical portfolio' raised eyebrows on platform-acquisition…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Domain antibody (dAbs) platform; GBP 230M; Cambridge UK biotech
Nearly 20 years and roughly $454M later, GSK's dAb platform bet has produced no approved drug — the flagship Domantis-derived TNFR1 program was discontinued after immunogenicity failures, and GSK even lost core dAb patent protection to rival Ablynx.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Domantis Limited (this deal) | 2006 | $454M | 24 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2006 deals · GlaxoSmithKline plc deals